Poland CBD regulations 2025: the reality behind the “0.3% THC” headline
Poland is often described as “hemp-friendly” because it aligns its industrial hemp threshold at ≤0.3% THC. That matters—but it does not solve the core commercial problem for most ingestible CBD brands.
In 2025–2026, the Polish market remains a tightrope walk between:
- an agricultural/controlled-substances framework that distinguishes industrial hemp from higher‑THC material;
- EU-wide food law where CBD extracts and cannabinoids are treated as Novel Food (meaning pre‑market authorization is typically required); and
- pragmatic enforcement where product form, claims, and documentation often determine whether you have a smooth customs clearance—or an expensive disruption.
This post is informational only and is not legal advice. Regulations and enforcement can change quickly; confirm current requirements with qualified counsel and the relevant Polish authorities.
What actually changed with the 0.3% THC alignment (and what didn’t)
Across the EU, the 0.3% THC threshold is widely used in agriculture policy for hemp cultivation eligibility. Poland has aligned its national approach to industrial hemp accordingly, but businesses should avoid oversimplifying that into “CBD is legal.”
What the alignment helps with
- Sourcing hemp raw material that fits a recognized “industrial hemp” category
- Reducing the risk that compliant hemp biomass is treated as a controlled narcotic based solely on cultivation threshold
What it does not solve
- Whether a finished CBD ingestible can be sold as a food or supplement (Novel Food barrier)
- Whether extracts (especially purified cannabinoids or “full spectrum” extracts) are treated as narcotics depending on THC content, intent, and analytical results
- Advertising and medical-claim restrictions
Key takeaway: THC threshold is necessary but not sufficient for a lawful retail strategy.
The Novel Food roadblock: why ingestible CBD remains high-risk
EU Novel Food classification is the central constraint
Under EU food law, many CBD extracts/cannabinoids are considered Novel Food (i.e., not consumed to a significant degree in the EU before May 15, 1997). Novel foods generally require a European Commission authorization before they can be placed on the market.
Useful references:
What this means in Poland in practice
Poland’s competent authorities for food safety and supplements can scrutinize ingestible CBD products through the lens of Novel Food. Even when a product’s THC is below 0.3%, Novel Food status can still block lawful sale if the specific ingredient/extract is not authorized.
If you plan to sell:
- CBD oils/tinctures for oral use
- gummies, beverages, chocolates, foods with added CBD
- food supplements with CBD isolate or hemp extract
…you should assume you will face Novel Food questions. In many cases, the most realistic “lawful” pathway is either (a) obtaining/using an authorized Novel Food ingredient supply chain or (b) not launching ingestibles until authorization exists.
The Polish authority touchpoint: State Sanitary Inspection and GIS
For foods and food supplements, oversight typically runs through the State Sanitary Inspection (Państwowa Inspekcja Sanitarna) and, nationally, the Chief Sanitary Inspectorate (GIS).
Practical impact:
- A supplement “notification” (common for many vitamins/herbals) is not the same as Novel Food authorization.
- Labels, claims, ingredient identity, and safety documentation can be challenged.
The viable SKU lane today: cosmetics/topicals (with strict claim control)
For late‑2025 and 2026 market entry, the most viable mainstream route is often cosmetics—provided you design the formula, claims, and supply chain to withstand scrutiny.
Why cosmetics can be viable
Cosmetics are governed under the EU Cosmetics Regulation (Regulation (EC) No 1223/2009), which creates a harmonized framework across EU Member States.
Key requirements include:
- a responsible person in the EU
- a Product Information File (PIF)
- safety assessment by a qualified assessor
- notification through the CPNP portal
- compliant labeling and claims
Reference: https://eur-lex.europa.eu/eli/reg/2009/1223/oj
Ingredient strategy: reduce narcotics and Novel Food exposure
A common “lower-friction” cosmetic strategy is to use hemp seed oil or other hemp-derived ingredients that do not present as purified cannabinoids, and to avoid positioning the product as delivering pharmacological effects.
Risk increases when you:
- use high-CBD extracts with measurable cannabinoid profiles
- market the product as “pain relief,” “anti-inflammatory,” “treats eczema,” or other medical-like effects
- imply systemic absorption or therapeutic dosing
Claims and marketing: where many brands fail
Under EU rules, cosmetic claims must be truthful, substantiated, and must not imply the product is a medicinal product.
Operational guardrails:
- Keep to cosmetic claims like moisturizing, soothing, skin barrier support
- Avoid disease/condition claims (psoriasis, arthritis, anxiety, insomnia, etc.)
- Avoid dosage-style language (mg per serving) for cosmetics
Polish enforcement can involve the State Sanitary Inspection at local level, especially when consumer safety or misleading claims are suspected.
Medical channel: tightly controlled, not a “CBD workaround”
Poland permits medical use of cannabinoid medicines under a controlled regime. This is not a general retail channel for CBD brands.
The key regulator touchpoint is the Chief Pharmaceutical Inspectorate (GIF).
What businesses should understand
- Medical products operate under pharmaceutical law requirements (authorization/quality/GMP, controlled distribution, pharmacy dispensing rules).
- Advertising is heavily restricted for prescription medicines and controlled products.
- Cultivation/import/manufacture routes are specialized, capital-intensive, and slow.
If your business plan is “we’ll sell ingestible CBD like a medicine,” expect a multi‑year, high‑cost program requiring regulated pharmaceutical capabilities.
Entity structuring and “local representation” playbook (late 2025–2026)
Decide: sell direct from another EU state or establish a Polish entity
Your structure will affect taxes, distribution, contracting, warehousing, and enforcement risk.
Common operating models:
- EU-based brand + Polish distributor: fastest; distributor holds local relationships and handles retail onboarding
- Polish sp. z o.o. (limited liability company): better long-term control; more admin and compliance overhead
- Hybrid: keep IP/brand in an EU holding company; set up a Polish sales entity for local execution
Cosmetics “Responsible Person” (RP)
If you are launching cosmetics, you need an EU Responsible Person. This can be:
- your Polish entity, if established and properly staffed
- a specialized compliance service provider in the EU
The RP is accountable for:
- PIF availability
- safety report
- label compliance
- CPNP notification
Practical timeline
For a well-managed cosmetics rollout:
- 4–8 weeks: formulation finalization + supplier qualification + stability/micro plan
- 4–6 weeks: safety assessment + PIF assembly (often overlaps)
- 1–2 weeks: artwork/label finalization + translation/INCI checks
- 1–2 weeks: CPNP notification + production release
Realistic total: 8–16 weeks, assuming you are not rebuilding the formula and your suppliers can deliver documentation quickly.
Customs and documentation: how to avoid narcotics classification problems
Even when a product is intended as a cosmetic, customs and enforcement questions can arise if documentation is weak or lab results are unclear.
Build a “customs-ready dossier” for each SKU
At minimum, maintain:
- Certificate of Analysis (CoA) from an ISO/IEC 17025-accredited lab showing cannabinoid profile and confirming THC is below your internal threshold
- full ingredient specification and supplier declarations (including origin of hemp input)
- GMP/ISO certificates for the manufacturer where applicable
- label artwork matching the actual product (language, responsible person, batch/PAO, warnings)
- PIF availability statement and CPNP confirmation (for cosmetics)
- MSDS/SDS where appropriate for logistics and workplace safety
Set internal THC controls stricter than the headline
Because analytical uncertainty and batch variation exist, many compliant operators use internal release limits below the legal maximum (e.g., “action limits”) to reduce the risk that a borderline batch tests over.
Operational steps:
- incoming ingredient testing
- in-process controls where feasible
- finished product batch testing
- retain samples and retention documentation
Product naming and presentation matters
Avoid:
- medical positioning
- strain-like naming conventions
- imagery that suggests intoxication or drug use
Even when lawful, presentation can increase scrutiny.
Retail and e-commerce: what to expect in Poland
For cosmetics/topicals
- Brick-and-mortar retailers often require a strong compliance packet (PIF availability, CoA, claims substantiation).
- Marketplaces may impose platform rules beyond law (restricted keywords, documentation requests, payment processor checks).
For ingestibles
Expect:
- higher delisting risk
- higher payment processing friction
- more frequent inquiries from local sanitary authorities
If you proceed, your risk controls should include:
- documented Novel Food position and ingredient authorization status
- conservative labeling and zero medical claims
- robust adverse event handling and recall readiness
Enforcement realities and penalties: plan for friction
Poland—like many EU markets—can see enforcement driven by:
- consumer complaints
- competitor complaints
- spot checks
- customs targeting
- misleading medical claims
Practical mitigations:
- keep documentation instantly retrievable (Polish/English where helpful)
- train customer service and sales teams to avoid therapeutic statements
- implement a “claims approval” workflow
- be ready to respond to inspector inquiries promptly
Cost expectations for a lawful entry (late 2025–2026)
Costs vary widely, but businesses should budget for compliance as a core launch expense.
Cosmetics/topicals budget ranges (typical)
- Safety assessment + PIF compilation: €1,500–€6,000 per product (range depends on formula complexity and provider)
- Stability/micro testing (as applicable): €500–€3,000
- Routine batch CoAs: €100–€400 per batch/test panel (lab and panel dependent)
- Regulatory/claims review: €1,000–€10,000+ depending on scope
Ingestibles budget reality
If you aim to be truly lawful via Novel Food authorization, costs can become significant (often six to seven figures over time) when you account for toxicology, dossier preparation, and multi-year timelines. Many brands instead delay ingestibles or partner with an ingredient supplier pursuing authorization.
Practical launch paths: three “playbooks” that work in Poland
Playbook A: Cosmetics-first (most reliable)
- Launch skin-care topicals with conservative claims
- Use low-friction hemp-derived ingredients and maintain strict CoA controls
- Build distribution relationships and brand presence
- Keep ingestibles out until authorization risk clears
Playbook B: “Compliance-led” ingestibles (highest effort)
- Confirm whether your CBD ingredient has a credible Novel Food authorization pathway
- Maintain a complete safety and traceability dossier
- Prepare for enforcement scrutiny and retailer/platform restrictions
Playbook C: Medical-channel strategy (specialized)
- Treat it as a pharma project, not a consumer goods launch
- Engage regulated partners and expect multi-year lead times
2025–2026 checklist: Poland market entry readiness
- SKU selection: prioritize cosmetics/topicals; treat ingestibles as Novel Food constrained
- THC controls: implement strict testing and conservative batch release limits
- Documentation: build a customs-ready dossier per SKU (CoA, specs, labels, PIF/CPNP where applicable)
- Claims governance: pre-approve marketing and customer support scripts
- Authority mapping: understand roles of GIS/State Sanitary Inspection (foods/cosmetics) and GIF (medical channel)
- Timeline planning: 8–16 weeks for cosmetics readiness; ingestibles may be multi‑year if pursuing authorization
Key takeaways
- Poland CBD regulations 2025 are defined as much by EU food law as by domestic THC thresholds.
- 0.3% THC alignment helps with hemp categorization but does not legalize ingestible CBD by itself.
- For late‑2025 to 2026, cosmetics/topicals are the most practical “go-to-market” lane when built with compliant ingredients, conservative claims, and strong documentation.
- Ingestibles remain the highest enforcement risk without a defensible Novel Food authorization position.
Next step: operationalize compliance with CannabisRegulations.ai
If you’re planning a Poland launch and need a structured way to track licensing, labeling, testing, claims, and market entry documentation, use https://cannabisregulations.ai/ to build a jurisdiction-specific compliance plan and keep your rollout audit-ready from day one.
